Peter Lawson
Stock Analyst at Barclays
(2.12)
# 2,941
Out of 5,147 analysts
102
Total ratings
44.94%
Success rate
-7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $316.99 | +27.76% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.71 | +1.34% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $101.27 | -0.27% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $32.20 | +24.22% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $12.06 | +107.30% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.65 | -60.78% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $44.06 | -9.21% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.99 | +50.75% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.48 | +35.14% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $9.41 | +6.27% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.86 | +3.63% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.77 | -53.01% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $32.30 | +60.99% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $8.73 | +26.00% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $13.27 | +20.57% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $5.73 | +161.78% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $20.37 | -31.27% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.37 | +118.98% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.06 | +183.02% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.68 | +138.10% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $102.02 | -41.19% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $10.26 | +65.69% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $15.97 | +94.11% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $11.14 | +16.70% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.76 | +81.16% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $5.37 | -34.82% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $134.46 | +171.46% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $30.23 | +52.17% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $68.98 | +552.36% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.20 | +1,945.45% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $60.14 | -25.17% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $316.99
Upside: +27.76%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.71
Upside: +1.34%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $101.27
Upside: -0.27%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $32.20
Upside: +24.22%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $12.06
Upside: +107.30%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.65
Upside: -60.78%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $44.06
Upside: -9.21%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.99
Upside: +50.75%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.48
Upside: +35.14%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $9.41
Upside: +6.27%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.86
Upside: +3.63%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.77
Upside: -53.01%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $32.30
Upside: +60.99%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $8.73
Upside: +26.00%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $13.27
Upside: +20.57%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $5.73
Upside: +161.78%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $20.37
Upside: -31.27%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.37
Upside: +118.98%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.06
Upside: +183.02%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.68
Upside: +138.10%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $102.02
Upside: -41.19%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $10.26
Upside: +65.69%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $15.97
Upside: +94.11%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $11.14
Upside: +16.70%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.76
Upside: +81.16%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $5.37
Upside: -34.82%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $134.46
Upside: +171.46%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $30.23
Upside: +52.17%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $68.98
Upside: +552.36%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.20
Upside: +1,945.45%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $60.14
Upside: -25.17%